Silodosin vs Tamsulosin as MET

Last updated: October 3, 2022
Sponsor: Princess Margaret Hospital, Hong Kong
Overall Status: Active - Recruiting

Phase

3

Condition

Kidney Stones

Treatment

N/A

Clinical Study ID

NCT05570084
KW/FR-19-075-(139-02)
  • Ages > 18
  • All Genders

Study Summary

The spontaneous passage rate for ureteral stone less than 1cm causing acute ureteral obstruction is about 50%. Previous Cochrane review has concluded that alpha blocker is likely to increase stone passage rate, reduce time to stone passage, analgesic use and hospitalisations. The European Association of Urology Guideline also recommends giving alpha blockers as Medical Expulsive Therapy to patients with distal ureteric stones >5mm. However there is heterogeneity in different alpha blockers.

Silodosin is a recently introduced selective alpha blocker which has a much higher selectivity for the alpha-1-A receptor (17-fold compared with tamsulosin). From previous animal studies, ureteral contraction is mainly mediated by the alpha-1-A receptor, hence silodosin maybe more effective in increasing stone passage compared with tamsulosin.

Previous studies and meta-analysis has shown superiority of silodosin over tamsulosin on earlier stone passage and less pain. However, there is no data on Chinese population.

The investigators would like to compare the efficacy and side effect profile of Silodosin versus tamsulosin on improving stone passage rate and hence reduce rate of further intervention for stone clearance.

Eligibility Criteria

Inclusion

Inclusion criteria:

  • Presented with radio-opaque ureteric stone of size 5mm to 10mm on KUB
  • Patients who can understand the study protocol and comply with the followup schedule

Exclusion

Exclusion criteria:

  • Radiolucent stone
  • Paper thin cortex
  • Non-functioning kidney
  • Renal insufficiency (serum creatinine greater than 1.8 mg/dl or 160umol/dL)
  • Concurrent urosepsis
  • Current [alpha]-blocker usage, Ca channel blocker, steroid
  • Pregnancy
  • Age < 18
  • History of ureteral stricture
  • History of ureteric stone treatment within 2 years
  • Allergic reaction to the study medication
  • Unable to Consent
  • Patient on JJ stent or PCN drainage

Study Design

Total Participants: 80
Study Start date:
May 31, 2022
Estimated Completion Date:
December 31, 2023

Connect with a study center

  • Hong Kong

    Hong Kong,
    Hong Kong

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.